Eli Lilly’s experimental oral weight loss pill helped patients lose about 12 percent of their body weight on average in a late-stage trial, the company said Thursday, positive results but still less ...

While a recent head-to-head trial of the obesity med heavyweights Wegovy and Zepbound favored the latter drug from Eli Lilly on weight loss, Novo Nordisk has now countered that result with ...

FILE PHOTO: FA combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk. REUTERS/Hollie Adams/Brendan McDermid/Combination/File ...

Eli Lilly reported a late-stage study of its oral weight-loss pill met primary and key secondary endpoints. The GLP-1 medication for obese or overweight patients with Type 2 diabetes lost an average ...

Eli Lilly says its experimental GLP-1 pill helped overweight adults with Type 2 diabetes shed 10.5% of body weight in a late-stage trial, after recent data from another study of the drug in patients ...

Eli Lilly’s experimental weight-loss pill could be fast-tracked under a one- to two-month review process recently launched by the U.S. Food and Drug Administration, several Wall Street analysts said.

(Reuters) -Eli Lilly will make its next-generation experimental weight-loss pill, orforglipron, at a new multi-billion-dollar manufacturing plant it plans to build in Texas, the company said on ...

Share on Pinterest GLP-1 drugmaker Eli Lilly’s new weight loss pill orforglipron showed meaningful weight loss results in a recent clinical trial. Scott Olson/Getty Images Eli Lilly’s new oral GLP-1 ...

VIENNA, Sept 17 (Reuters) - Eli Lilly's (LLY.N), opens new tab bid for approval for an experimental weight-loss pill got a boost on Wednesday with new clinical trial data, and the company reaffirmed ...